This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Pfizer to Buy Array BioPharma, Broaden Cancer Portfolio
by Zacks Equity Research
Pfizer (PFE) offers $48 per share to buy Array BioPharma and strengthen its cancer portfolio.
Top Analyst Reports for Broadcom, Amgen & NVIDIA
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Broadcom (AVGO), Amgen (AMGN) and NVIDIA (NVDA).
3 Big Pharma Stocks to Buy Right Now
by Zachary Stutler
These big pharma stocks all have a Zacks Rank #2 or better.
Mallinckrodt Presents Encouraging Data on Acthar Gel for RA
by Zacks Equity Research
Mallinckrodt (MNK) reports encouraging results from a phase IV study on Acthar for RA at the EULAR.
Roche Reports Positive Data on Rituxan for Pemphigus Vulgaris
by Zacks Equity Research
Roche (RHHBY) announces positive data on rheumatic diseases drug, Rituxan, for pemphigus vulgaris.
Roche's Rituxan Gets Priority Review for Blood Disorder
by Zacks Equity Research
Roche (RHHBY) gets Priority Review status from the FDA for Rituxan in children with two rare blood vessel disorders.
Novartis Reports Data on Cosentyx for Psoriatic Arthritis
by Zacks Equity Research
Novartis (NVS) announces new data on psoriatic arthritis drug, Cosentyx.
Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol-Myers Squibb (BMY) closed at $47.63, marking a +1.62% move from the previous day.
Zacks.com featured highlights include: CDW, Bristol-Myers, Celgene, PepsiCo and Northrop
by Zacks Equity Research
Zacks.com featured highlights include: CDW, Bristol-Myers, Celgene, PepsiCo and Northrop
Bristol-Myers Squibb (BMY) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
Boost Your Portfolio's Health With These 3 Big Drug Stocks
by Kinjel Shah
The large-cap pharma industry is doing well in 2019. Here are three stocks from the space that investors may consider betting on.
Insys Down on Bankruptcy News Amid Increasing Legal Expenses
by Zacks Equity Research
Insys (INSY) crashes as it files for bankruptcy protection amid rising legal settlement dues.
Merck (MRK) to Buy Private Biotech Tilos for Up to $773M
by Zacks Equity Research
Merck (MRK) set to buy private preclinical biotech Tilos Therapeutics in a deal that could be worth up to $773 million
Top 5 ROE Stocks to Buy as US-Mexico Trade Concerns Abate
by Supriyo Bose
ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.
Sanofi (SNY) in Focus: Stock Moves 5.5% Higher
by Zacks Equity Research
Sanofi (SNY) shares rose nearly 6% in the last trading session, amid huge volumes.
The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca
Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache
by Kinjel Shah
Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.
Novartis Appoints New Pharma Unit Head, Gives Other Updates
by Zacks Equity Research
Novartis (NVS) appoints Marie-France Tschudin as head of the pharma unit. The company also provides a few pipeline updates.
Bristol-Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Bristol-Myers Squibb (BMY) closed at $46.15 in the latest trading session, marking a -1.03% move from the prior day.
Celgene & Acceleron's BLA for Luspatercept Accepted by FDA
by Zacks Equity Research
Celgene (CELG) along with partner Acceleron submits application for luspatercept to the FDA.
Mallinckrodt Down After Agreement with DOJ for Litigation
by Zacks Equity Research
Mallinckrodt (MNK) expects to pay $15.4 million to DOJ in relation with the Questcor litigation.
Was ASCO Quieter for Big Drug/Biotech Stocks This Year?
by Kinjel Shah
The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.
Cancer-Fighting Stocks & ETF: What You Need to Know
by Neena Mishra
Many biotech stocks soared after they presented very promising cancer treatment results at the ASCO conference
Celgene (CELG) Presents Data on Pipeline Candidates at ASCO
by Zacks Equity Research
Celgene (CELG) presents data on myelofibrosis candidate from a phase II study and an oncology candidate at ASCO.
Aduro Stock Crashes After ASCO Updates on Cancer Candidate
by Zacks Equity Research
Aduro (ADRO) presents updated data from an ongoing phase Ib study evaluating its STING agonist, ADU-S100 in combination with Novartis' checkpoint inhibitor.